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Background: Patients with autism spectrum disorder (ASD) may have low brain serotonin concentrations as
reflected by the serotonin end-metabolite 5-hydroxyindolacetic acid (5HIAA) in cerebrospinal fluid (CSF).
Methods: We sequenced the candidate genes SLC6A4 (SERT), SLC29A4 (PMAT), and GCHFR (GFRP), followed by
whole exome analysis.
Results: The known heterozygous p.Gly56Ala mutation in the SLC6A4 gene was equally found in the ASD and control
populations. Using a genetic candidate gene approach, we identified, in 8 patients of a cohort of 248 with ASD, a high
prevalence (3.2%) of three novel heterozygous non-synonymous mutations within the SLC29A4 plasma membrane
monoamine transporter (PMAT) gene, c.86A > G (p.Asp29Gly) in two patients, c.412G > A (p.Ala138Thr) in five patients,
and c.978 T > G (p.Asp326Glu) in one patient. Genome analysis of unaffected parents confirmed that these PMAT
mutations were not de novo but inherited mutations. Upon analyzing over 15,000 normal control chromosomes, only
SLC29A4 c.86A > G was found in 23 alleles (0.14%), while neither c.412G > A (<0.007%) nor c.978 T > G (<0.007%) were
observed in all chromosomes analyzed, emphasizing the rareness of the three alterations. Expression of mutations
PMAT-p.Ala138Thr and p.Asp326Glu in cellulae revealed significant reduced transport uptake activity towards a variety
of substrates including serotonin, dopamine, and 1-methyl-4-phenylpyridinium (MPP+), while mutation p.Asp29Gly had
reduced transport activity only towards MPP+. At least two ASD subjects with either the PMAT-Ala138Thr or the
PMAT-Asp326Glu mutation with altered serotonin transport activity had, besides low 5HIAA in CSF, elevated serotonin
levels in blood and platelets. Moreover, whole exome sequencing revealed additional alterations in these two ASD
patients in mainly serotonin-homeostasis genes compared to their non-affected family members.
Conclusions: Our findings link mutations in SLC29A4 to the ASD population although not invariably to low brain
serotonin. PMAT dysfunction is speculated to raise serotonin prenatally, exerting a negative feedback inhibition through
serotonin receptors on development of serotonin networks and local serotonin synthesis. Exome sequencing of
serotonin homeostasis genes in two families illustrated more insight in aberrant serotonin signaling in ASD.
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Autism spectrum disorder (ASD), which includes infantile
autism (Kanner syndrome), Asperger’s syndrome, and
pervasive developmental disorder – not otherwise spe-
cified (PDD-NOS), are a group of complex and lifelong
neuro-developmental disorders characterized by deficits
within three core domains, social interaction, verbal and
non-verbal communication, as well as limited interests
and repetitive, stereotypic behavior [1,2]. Numerous family
and twin studies have reported that ASD are highly
heritable disorders and suggest that approximately 90%
of variance is attributable to genetic factors [3], while
other studies reported a much more moderate genetic
heritability and a substantial shared twin environmental
component [4]. Despite the strong genetic evidence, the
identity and number of genes involved or responsible for
ASD are not yet known [1]. Nevertheless, it is generally
assumed that the genes involved in the pathogenesis of
autism are implicated in the overall processes of neuronal
signal transmission, including molecules such as synaptic
scaffolding proteins, cell adhesion molecules, protein
involved in second-messenger systems, secreted proteins,
receptors, and transporters [5].
Serotonin, as a monoamine neurotransmitter and hor-
mone, plays numerous roles and is a critical modulator
of neuronal interaction that supports diverse behaviors
and physiological processes, and acts via different specific
transporters, receptors, and intracellular signaling path-
ways. Multiple lines of evidence implicate abnormal sero-
tonergic signaling in psychiatric and neuro-developmental
pathogenesis. However, the entire serotonin system is
poorly defined and is far from a complete understanding.
Laboratory analyses of cerebrospinal fluid (CSF) describe
a frequency of up to 20% of patients with altered serotonin
end-metabolite 5-hydroxyindolacetic acid (5HIAA) in
neurological disorders, including subjects with ASD [6]
(for a broader overview on monoamine neurotransmitter
disorders see reference [7] and references therein). Sero-
tonin re-uptake transporter genes, such as SERT-SLC6A4
and PMAT-SLC29A4, are of special interest for ASD for at
least three reasons [8]: i) Serotonin has been shown to
regulate the development of the central nervous system
[9] and to be involved in a broad spectrum of behavioral
and psychological processes (e.g., social behavior, aggres-
sion and anxiety) and various psychiatric disorders [10].
ii) Several studies have reported that approximately one-
third of all autistic patients have elevated levels of whole
blood (or platelet) serotonin [11,12]. Hyperserotonemia,
which is believed to be caused by abnormal maturation of
the serotonin system [9,12], is also suggested to be either
directly or indirectly responsible for the immune abnormal-
ities observed among autistic subjects [13]. Additionally,
developmental changes in brain serotonin synthesis capacity
measured by PET using the radioactive marked serotoninprecursor (α[11C]-methyl-L-tryptophan) showed a dimin-
ished capacity of whole-brain or regional brain serotonin
synthesis in autistic children compared to non-autistic
children, thus suggesting that developmental regulation of
serotonin synthesis is involved in the pathogenesis of aut-
ism [14]. iii) Increased repetitive behaviors and irritability
were observed in autistic patients when subjected to a
dietary depletion of the serotonin precursor tryptophan
due to an expected reduction in extracellular serotonin
availability [15]. Further support for a link between brain
hyposerotonemia and a possible relevance to autism comes
from mice deficient in neuronal tryptophan hydroxylase 2
(Tph2-/-), which lack brain serotonin, and showed substan-
tial deficits in social interaction and communication, and
also displayed highly repetitive and compulsive behaviors
[16]. Increased extracellular serotonin availability due
to administration of selective serotonin re-uptake inhibitors
led to reduced symptoms of irritability and rigid-compul-
sive behavior in individuals with ASD [15,17]. Altogether,
these findings emphasize that abnormal serotonergic trans-
mission may be important in the pathogenesis of autism
[18,19]. Due to the serotonin hypothesis of autism, genes
encoding proteins involved in brain serotonin metabolism
and neurotransmission have received more attention than
other categories of genes [20].
In this context, we found that isolated low brain sero-
tonin concentration, as reflected by the 5HIAA in the
CSF, is associated with PDD-NOS and the functional
(heterozygous) c.167G > C (p.G56A) mutation of the
serotonin re-uptake transporter gene (SERT/SCL6A4)
combined with a homozygous long (L/L) SERT gene-
linked polymorphic promoter (5-HTTLPR) region [21].
Moreover, daily treatment with serotonin precursor 5-
hydroxytryptophan and aromatic amino acid decarboxylase
(AADC) inhibitor carbidopa led to clinical improvements
and normalization of the 5HIAA levels in the CSF and
urine, indicating that the brain serotonin turnover was
normalized [22]. In an attempt to gain some insight into
the brain serotonin physiology and underlying mechanisms
of abnormal brain metabolism, we report in patients with
ASD and low brain 5HIAA mutations in the serotonin
transporter SCL29A4, an observation that may provide
some bases for improving the application of various thera-
peutic tools.
Methods
Patients involved and work-flow
Figure 1 depicts a flow-chart of the study, including selec-
tion of the participating patients from the three cohorts in
Liège, Paris, and Zürich, the results of CSF findings in 98
patients, and the collection of DNA samples from patients
and controls. All patients have been diagnosed with ASD
according to DSM-IV and ICD-10 criteria followed by
comprehensive investigations using the Autism Diagnostic
Figure 1 Diagnostic flow-chart of ASD in 248 patients (see text for details). *One patient with p.D326E (PMAT) and p.G56A (SERT). **Using
genomic DNA from an independent cohort from the Children’s Hospital in Zurich of 394 unaffected control subjects (a total of 788 chromosomes).
***see http://www.1000genomes.org; phase1 integrated release version3 20120430. ****see http://evs.gs.washington.edu/EVS/; accessed August 2012
(EVS-v.0.0.14); see also reference [23].
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test procedure. Further details can be obtained from
Additional file 1.
Screening for mutations in the human SLC29A4 gene
Intronic primers were designed with the online program
ExonPrimer (http://ihg.gsf.de/ihg/ExonPrimer.html) to
flank the exons in the human SLC29A4 gene (PMAT/
SLC29A4; OMIM: 609149; ENST00000297195) (for more
details see Additional file 2: Table S1). PCR reactions were
performed in a final volume of 25 μL containing 1 μL of
genomic DNA template (100 ng), 1 μL of each primer
(forward and reverse) (5 μM), 0.5 μL 10 mM deoxyri-
bonucleoside triphosphates, 0.2 μL Hot FirePolHotstart
DNA polymerase (Solis Biodyne, Tartu, Estonia), 1.5 μL
25 mMMgCl2, 2.5 μL 10× reaction buffer (Mg
2+ free from
Solis Biodyne), and 5 μL 5× Q-solution (Qiagen, Hilden,
Germany). The PCR reactions were performed in a
GeneAmp PCR System 9700 from (Life Technologies,
Zug, Switzerland) using standard thermal cycling: hot
start activation at 95°C for 15 minutes, followed by
35 cycles of denaturation 95°C for 1 minute, annealing
55°C for 45 seconds, and extension at 72°C for 1 minute,a final extension was performed at 72°C for 10 minutes
and termination at 4°C. The same forward and reverse
primers as mentioned above were used to sequence
the amplified PCR products with BigDye Terminator
v1.1 Cycle Sequencing Kit (Applied Biosystems). Sequen-
cing PCR was performed in a 10 μLreaction mixture
consisting of 0.5 μL PCR product, 0.8 μL primer (5 μM),
1.5 μLBigDye, and 1.25 μL5× sequencing buffer (BigDye
and 5 × sequencing buffer were both from BigDye Termin-
ator v1.1 Cycle Sequencing Kit from Applied Biosystems)
using standard thermal cycling: (activation at 95°C for
1 min, followed by 25 cycles of 96°C for 10 seconds, 50°C
for 5 seconds, 60°C for 3 minutes and termination at 4°C).
After end run, 15 μL H2O was added to the sequencing
reactions before purified by gel filtration (using MultiScreen
HV 96-well filter plates (Merck Millipore, Darmstadt,
Germany) with Sephadex G-50 (GE Healthcare, Little
Chalfont, UK) and analyzed on a 3130xl Genetic Analyzer
(Applied Biosystems). Sequencing results were compared
with wild-type sequence of the SLC29A4 gene by using
Mutation Surveyor (Demo) Software v3.20 from SoftGe-
netics (State College, PA, USA; Transcript ID: ENST
00000297195 or accession number NM_001040661). In
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the data of the 1000 Genomes Project (http://www.1000
genomes.org; phase1 integrated release version3 20120430)
and the Exome Variant Server of the Exome Sequencing
Project (http://evs.gs.washington.edu/EVS/; accessed August
2012; see also reference [23]).
Screening for mutations in the human SLC6A4 gene
Screening of genomic DNA for mutations as well as
detection of non-coding VNTR gene polymorphisms
(5-HTTLPR and STin2 VNTR) in the human SLC6A4
gene (SERT/SLC6A4; OMIN: 182138; ENST00000394821)
were performed as described previously [21].
Generation of mutant PMAT by site-directed mutagenesis
To facilitate the determination of membrane localization,
PMAT mutants were constructed using yellow fluorescence
protein (YFP)-tagged wild-type human PMAT-cDNA as
template. YFP was tagged at the N-termini of the wild-type
and mutant PMAT transporters, as previous studies have
shown that the YFP tagging had no effect on substrate
selectivity and kinetic behaviors of the transporter [24].
The wild-type human PMAT-cDNA was previously sub-
cloned into the YFP vector pEYFP-C1 (Clontech, Palo
Alto, CA, USA) [25]. PMAT-D29G, A138T, and D326E
mutations were introduced into wild-type PMAT/pEYFP-
C1 vector by site-directed mutagenesis and verified by
DNA sequencing.
Stable expression in Madin-Darby canine kidney (MDCK) cells
YFP-tagged mutant constructs were transfected into MDCK
cells using Lipofectamine 2000 transfection reagent
(Invitrogen, Carlsbad, CA, USA). Stably transfected cell
lines were obtained by culturing cells in minimal essential
medium containing 10% fetal bovine serum and G418
(1,000 μg/mL). Empty pEYFP-C1 vector was transfected
into MDCK cells to obtain the control cell line. After 2 to
3 weeks of drug selection, fluorescence-positive cells were
purified by a FACS Vantage SE sorter (BD Biosciences,
San Jose, CA, USA) at the Cell Analysis Center at the
University of Washington, Health Sciences Center. The
sorted cells were cultured and maintained in minimal
essential medium containing G418 (200 μg/mL).
Confocal fluorescence microscopy
To determine the cellular localization of YFP-tagged
mutant transporters, ~2 × 105 cells were grown on top
of a microscope cover glass in 6-well plates (Falcon, BD
Biosciences, Bedford, MA, USA) for 2 to 3 days until
confluent. Cells were mounted onto microscope glass
slides with Fluoromount-G (Electron Microscopy Sciences,
Hatfield, PA, USA) and visualized with a Leica SP1 confocal
microscope equipped with an argon laser as the light
source at the Keck Microscopy Facility at the Universityof Washington. Images were captured by excitation at
488 nm and emission at 515 nm.
Functional characterization in MDCK cells
Stably transfected MDCK cells were plated in 24-well
plates and allowed to grow for 2 to 3 days until confluent.
Growth medium was aspirated and each well was rinsed
once with Krebs-Ringer-Henseleit buffer (5.6 mM glucose,
125 mM NaCl, 4.8mMKCl, 1.2 mM KH2PO4, 1.2 mM
CaCl2, 1.2 mM MgSO4, 25 mM HEPES, pH 7.4) and
preincubated in the same buffer for 15 min at 37°C.
Transport assays were performed at 37°C by incubating
cells in KRH buffer containing a 3H-labeled ligand.
[3H]MPP+ (85 Ci/mmol) was obtained from American
Radiolabeled Chemicals, Inc. (St. Louis, MO, USA).
[3H]5-HT (5-hydroxy-[1,2-3H] tryptamine creatinine
sulfate, 28.1 Ci/mmol) and [3H] dopamine (3,4-dihydroxy-
[2,5,6-3H] phenylethylamine, 51.3 Ci/mmol) were obtained
from PerkinElmer (Life Sciences Inc., Waltham, MA, USA).
All other chemicals were obtained from Sigma (St. Louis,
MO, USA). Uptake was terminated by washing the cells
three times with ice-cold KRH buffer. Cells were then
solubilized with 0.5 mL of 1 N NaOH and neutralized
with 0.5 mL of 1 N HCl. Radioactivity in the cell lysate
was quantified by liquid scintillation counting. Protein
concentration in each well was measured using BCA
protein assay kit (Pierce, Rockford, IL, USA) and the
uptake in each well was normalized to its total protein
content. In all studies, cells transfected with an empty
vector served as a background control. Transporter-specific
uptake was calculated by subtracting the background
uptake in vector-transfected cells. For all uptake experi-
ments, data were expressed as the mean ± SD from
three independent experiments (n = 3) with different
cell passages. For each experiment, uptake was carried
out in triplicates on the same plate. Where applicable,
P values were obtained through Student’s t-test using
Prism software (GraphPad Software Inc., La Jolla, CA,
USA). P values <0.05 were considered significant.
Isolation of plasma membrane proteins by cell surface
biotinylation
Stably transfected MDCK cells were plated onto 60 mm
plates and cultured until confluent. Cells were washed
twice with 3 mL of ice-cold PBS/CM (138 mM NaCl, 2.7
mMKCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, 0.1 mM
CaCl2, 1 mM MgCl2, pH 8.0). Biotinylation was carried
out on ice by incubation with 1 mL of ice-cold PBS/CM
containing a membrane-impermeable biotinylation reagent
Sulfo-NHS-SS-biotin (0.5 mg/mL) (Pierce). After two
successive 20 min incubations at 4°C with freshly pre-
pared NHS-SS-biotin and gentle shaking, cells were
briefly rinsed with 3 mL of PBS/CM containing 100 mM
glycine. Cells were further incubated at 4°C with the same
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unreacted NHS-SS-biotin. Cells were then solubilized on
ice by incubating in 1 mL of lysis buffer containing
20 mM Tris, 150 mMNaCl, 1 mM EDTA, 1% Triton X-
100, 1 mMphenylmethyl-sulfonyl fluoride, and Protease
Inhibitors Cocktail (Roche) for 1 h with occasional vortex-
ing. Protein concentrations were measured from the
supernatant lysate and 50 μL of UltraLink Immobilized
NeutrAvidin protein (Pierce) was then added to the super-
natant for the isolation of membrane proteins. Membrane
proteins were subjected to Western blot using a mouse
monoclonal anti-yellow fluorescent protein antibody (JL-8)
(BD Biosciences) at 1:1,000 dilution, followed by horserad-
ish peroxidase-conjugated goat anti-mouse IgG (1:20,000
dilution). The chemiluminescent signals in the Western
blots were detected by using SuperSignal West Pico
Chemiluminescent Substrate (Pierce) followed by exposure
of the blots to X-ray films. Band intensity was quantified
by densitometry using the ImageQuant software (Molecu-
lar Dynamics, Thermo Fisher Scientific Inc, Rockford, IL,
USA). As reported previously [24], double or multiple pro-
tein bands around the expected molecular size (~75 kDa)
were observed for the YFP-tagged PMAT proteins, which
could be due to differential glycosylation of PMAT.
Whole exome sequencing and sequence analysis
Whole exome sequencing was performed in the two ASD
cases MT and PL with isolated low serotonin and carrying
PMAT-A138T or D326E, plus their unaffected parents
and siblings (for more details see Additional file 3:
Figure S4). The color space sequence reads (paired
end 50 × 35) were mapped to the human genome as-
sembly hg19 (http://hgdownload.cse.ucsc.edu/golden-
Path/hg19/bigZips/chromFa.tar.gz) using the software
Bioscope 1.2.1 from Applied Biosystems (Life Technologies,
Carlsbad, CA, USA). After mapping, the single nucleotide
polymorphisms (SNPs) were called by using the DiBayes
algorithm (Life Technologies) with high and medium strin-
gency settings. The obtained SNPs were classified into
intronic, intergenic, coding (synonymous and non-
synonymous amino acid substitutions), and splice-site vari-
ants with a custom software pipeline. Furthermore, all
SNPs were compared to dbSNP build 132, OMIM, and
clinically relevant mutation.
Results
Analysis of CSF and sequencing of SLC6A4, SLC29A4, and
GCHFR genes
To follow-up our previous findings or association [21], i.e.,
ASD and abnormally low brain serotonin metabolites with
potential treatment possibilities, we analyzed a Caucasian
cohort of 248 patients diagnosed with ASD – a diagnostic
flow-chart of these patients is depicted in Figure 1. We
sequenced genomic DNA using a genetic candidate geneapproach including genes encoding SERT (SCL6A4), plasma
membrane monoamine transporter PMAT (SLC29A4),
and GTP cyclohydrolase I feedback regulatory protein
GFRP (GCHFR), as they might be involved in serotonin
homeostasis. The latter was proposed to be involved
specifically in serotonin neurons and not within dopamine
neurons to regulate the tetrahydrobiopterin biosynthesis
[26]. Up to now, no mutations have been reported within
the GCHFR and SLC29A4 genes; however, SLC29A4 is
located on chromosome position 7p22.1 [25], where asso-
ciation studies identified a susceptibility locus for ASD
[27]. Among the initially diagnosed 300 ASD-affected
patients, a subset of 97 subjects (=100%) underwent a
lumbar puncture for CSF analysis of monoamine metabo-
lites, pterins, and folate levels after obtaining informed
consent (Additional file 1). The CSF analysis indicated
normal values in 47 (48%) subjects and isolated low
5HIAA concentration in 26 (27%). Further, isolated low
folate in CSF was found in 20 subjects (21%), and both
low folate and low 5HIAA values in CSF were present
in 4 subjects (4%). Pterin levels among all patients were
normal. Mutations in genes encoding AADC and mono-
amine oxidase A were considered unlikely based on normal
catecholamines, homovanillic acid, 5OH-tryptophan, and
5HIAA levels in CSF for the subjects analyzed, and were
therefore discarded.
Among the genetically investigated 248 ASD cases, all
exons and exon-intron boundaries of SLC6A4, SLC29A4,
and GCHFR were sequenced using standard methods
(Additional file 1). Further, no mutations in GCHFR were
found in the study cohort (not shown). However, we iden-
tified a single heterozygous non-synonymous mutation in
the SLC29A4 gene in eight ASD patients (3.2% in our
cohort of 248 subjects): two carrying c.86A > G, five
patients, including two identical twin brothers, with
c.412G > A, and one that had the c.978 T > G sequence
alteration, determining p.Asp29Gly, p.Ala138Thr, and
p.Asp326Glu residue changes of PMAT, respectively
(OMIM 609149; ENST00000297195) (Additional file 4:
Figure S1). Although the identical twins and three other
patients with the most frequent occurring PMAT p.
Ala138Thr mutation came from different unrelated
families, we have not performed an analysis of genetic
markers to confirm a founder effect. In addition, five
subjects (2%) of the 248 ASD-affected patients were
heterozygous for the SLC6A4 base change c.167G > C,
encoding p.Gly56Ala (Additional file 2: Table S2),
which did not differ significantly from the frequency of
2.3% in the control populations, and has already been
associated with autism and rigid-compulsive behaviors
[28]. In a single patient (PL), a double heterozygosity was
observed, since both SLC6A4 c.167G > C and SLC29A4
c.978 T >G were found (Additional file 2: Table S2).
Whereas the SLC6A4 c.167G > C (SERT-G56A) alteration
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serotonin re-uptake [28], mutations within the SLC29A4
gene have not been described before, thus making these
three novel mutations the first of their kind. Using gen-
omic DNA from an independent group of 394 unaffected
control subjects (a total of 788 chromosomes) (Additional
file 1), we ruled out the possibility that the SLC29A4
mutations c.86A > G, c.412G > A, and c.978 T > G are
frequent SNPs, as none of these variants were detected
in our control cohort. Additionally, after a search in the
1000 Genomes Project and Exome Sequence Project data
(a total of 2,188 plus 13,006 chromosomes respectively)
only SLC29A4 c.86A >G was found in 23 alleles (<0.16%)
in the database of the Exome Variant Server, while neither
c.412G > A (<0.007%) nor c.978 T > G (<0.007%) were
observed in all chromosomes analyzed (Additional file 1).
These results emphasized the rareness of the three muta-
tions described here. In addition to SLC29A4 c.86A >G,
c.412G >A, and c.978 T >G mutations, PMAT-M24L
(rs73332823), which was found in 2% of our ASD-affected
cohort (5/248) but also in 1.4% of our control chromo-
somes (43/2976; not shown), strongly suggested that it
simply represents a common SNP.
Evolutionary conservation analysis and functional
evaluation of PMAT mutants
The newly discovered amino acid changes p.D29G, p.
A138T, and p.D326E in PMAT are located in the N-
terminus, third membrane-spanning domain and the large
cytoplasmic loop between transmembrane domains 6 and
7 in the PMAT protein respectively (Additional file 5:
Figure S2). Alignment of the fully annotated PMAT
protein sequences from seven species showed that D29
and D326 are well conserved across mammalian species
whereas A138 is less conserved (Additional file 6:
Figure S3). Using two publically available prediction
algorithms, MutationTaster [29] and PolyPhen2 [30],
the D29G and the D326E mutations were predicted to
have more deleterious effects than the A138T mutation
(Additional file 2: Table S3). These regions have previously
been shown to contain important sites for PMAT sub-
strate recognition and transport [24,31]. Nevertheless,
to experimentally investigate the functional impact of
these mutations, the PMAT alterations p.D29G, p.A138T,
and p.D326E were constructed, expressed in MDCK cells
and analyzed in terms of subcellular localization and
transport activity in comparison with PMAT-wild-type
(Figure 2a–c). Cell surface biotinylation and Western blot
analysis demonstrated comparable plasma membrane
expression of PMAT-wildtype and PMAT-D29G, PMAT-
A138T, and PMAT-D326E mutant proteins (Figure 2a).
When expressed in MDCK cells and observed by confocal
microscopy, the three mutated PMAT proteins were
located in the plasma membrane similar to PMAT-wildtype (Figure 2b), demonstrating that these single
amino acid alterations p.D29G, p.A138T, and p.D326E
do not alter protein stability and trafficking to the plasma
membrane. To assess the functional consequence of the
PMAT mutations, we compared the uptake activity of
wild type and mutant proteins towards a variety of radi-
olabeled substrates including serotonin, dopamine, and
MPP+ (1-methyl-4-phenylpyridinium) (Figure 2c). The
functional studies revealed that both PMAT-A138T and
PMAT-D326E exhibited similarly reduced transport activity
towards all three substrates tested (serotonin, dopamine,
and MPP+), suggesting that the two mutants induce an
overall reduction in transport activity and are functionally
indistinguishable from each other. In contrast, PMAT-
D29G showed serotonin and dopamine transport activities
similar to that of PMAT-wildtype, but its transport activity
toward MPP+ was found to be reduced similar to that
of PMAT-A138T and PMAT-D326E. The more-than-
predicted damaging effect of the A138T mutation is likely
due to its position on TM 3 (Additional file 5: Figure S2)
which lies within a region that has previously been shown to
contain important sites for PMAT substrate recognition and
transport [24,31]. In addition, previous analysis of natural
variations in a number of human membrane transporter
genes has suggested that TM regions have special evolu-
tionary and functional constraints. Compared to the loop
regions, there are much less variations observed in the TM
regions, even in evolutionarily unconserved residues [32].
Whole exome sequencing of families with detected PMAT
mutations
While SERT-G56A is known to cause an up-regulation for
serotonin transport (gain of function) [28], our functional
data suggest that the two PMAT mutations (PMAT-
A138T and PMAT-D326E) induce reduced transport
activity towards serotonin. All sequence alterations we
have identified in SLC6A4 and SLC29A4 were present
in their heterozygous states (Additional file 4: Figure S1).
From segregation studies by genomic DNA sequencing
analysis of the parents of the ASD-affected patients, it
appears that the mutations in SLC6A4 and SLC29A4
are inherited and are not de novo mutations. Like in
several locus-specific CNV-related ASD, heritability does
not seem to follow a simple autosomal dominant mode of
inheritance and suggests rather a complex heritability and
haplotype association. Furthermore, we observed elevated
serotonin levels both in blood (ng/mL) and platelets
(ng/×109) in two of the ASD-affected patients MT and
PL (Table 1), which also were found to carry common
non-coding variable number tandem repeat (VNTR)
polymorphisms within the SLC6A4 gene (5-HTTLPR L/
S and STin2 VNTR 10/12 variants; Additional file 2:
Table S2 and Additional file 3: Figure S4). The elevated
serotonin found in blood and platelets supports previous
c**
*
** *
**
**
b
PMAT WT EYFP-C1A138T D326ED29G
a
PMAT WT     D29G      A138T      D326E    EYFP-C1
Figure 2 Discovery and functional characterization of PMAT mutations from ASD patients. Out of 248 patients diagnosed with ASD and
normal or isolated low 5HIAA in the CSF, 8 patients were carrying a heterozygous mutation in the SLC29A4 gene encoding for PMAT: c.86A > G/p.
D29G in 2 subjects, c.412G > A/p.A138T in 5 subjects, and c.978 T > G/p.D326E in 1 subject, indicating a cumulative prevalence of 3.2% in our analyzed
cohort of ASD patients (Additional file 4: Figure S1). (a) Cell surface biotinylation and Western blot analysis demonstrated comparable plasma membrane
expression of PMAT-wildtype (wt), PMAT-D29G, PMAT-A138T, and PMAT-D326E proteins. Empty pEYFP-C1 vector was transfected into MDCK cells to
generate the control cell line. (b) Confocal microscopy imaging of MDCK cells expressing PMAT-wt, PMAT-D29G, PMAT-A138T, PMAT-D326E, and
empty pEYFP-C1 vector. The three mutated PMAT proteins revealed normal localization in the plasma membrane similar to PMAT-wt. Scale bars: 20 μm.
(c) Serotonin (5-HT), dopamine and 1-methyl-4-phenylpyridinium (MPP+) transport activity were significantly reduced in MDCK cells transfected with
PMAT-A138T and PMAT-D326E. For all the transport activity experiments, the values are indicated in mean ± SD from three independent experiments
(n = 3) with different cell passages. For each experiment, uptake was carried out in triplicates on the same plate. Significant difference from the
corresponding value for PMAT-wt (100% transport activity) is indicated by asterisks: *, P < 0.05 and **, P < 0.01 (Student’s t-test).
Adamsen et al. Molecular Autism 2014, 5:43 Page 7 of 11
http://www.molecularautism.com/content/5/1/43studies showing that one-third of all ASD-affected individ-
uals have hyperserotonemia [11,12].
To understand the underlying inheritance, we performed
whole exome sequencing of the two ASD cases with
isolated low brain serotonin turnover and carrying the
PMAT-A138T or D326E mutation, plus their unaffected
parents and siblings. The data were filtered for non-synonymous amino acid substitutions within published
serotonin-related and/or autism-associated candidate genes
(Additional file 7: Tables S4 and S5). Furthermore, using
NCBI population diversity, non-synonymous mutations
with an allele frequency <1 were excluded. We used a
hypothetical “genetic-accumulation-model” with all the
non-synonymous findings from the serotonin-related and/
Table 1 Summary of metabolic findings in patient MT (Asperger’s) and PL (PDD-NOS)
Patient Age (years) 5HIAA (nmol/L) HVA (nmol/L) HVA/5HIAA (ratio) Serotonin
Blood (ng/mL) Platelets (ng/×109)
MT 9.6 64.7 389.6 6.0 287 1041
PL 6.2 73.6 399.8 5.4 221 675
Ref* 5–10* 133 (88–178)* 523 (144–801)* 1.5–3.5* 50–220** 125–500**
HVA, homovanillic acid; 5HIAA, 5-hydroxyindolacetic acid (serotonin end-metabolite).
*Reference values and ranges see ref. [33].
**Reference values see ref. [34].
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Additional file 7: Tables S4 and S5. Alterations with an
allele frequency <1 were amalgamated (“total gene hits”) in
the two affected patients plus their unaffected family mem-
bers (parents and sisters) (Additional file 3: Figure S4).
Using such limited analyses, the cumulative genetic burden
of the two ASD affected patients showed a tendency to-
wards more “serotonin gene hits”, indicating alterations in
mainly serotonin homeostasis compared to the other family
members (Additional file 3: Figure S4).
Discussion
In contrast to an equal distribution of the previously
described SLC6A4 p.G56A mutation among the ASD
and control population, in this study we identified and
linked three novel heterozygous PMAT mutations to
ASD and demonstrate in vitro functional loss of sero-
tonin and dopamine re-uptake in two mutations. The most
frequently encountered mutation p.A138T in SLC29A4/
PMAT could be identified among four unrelated families
although we did not investigate the possibility of a common
founder mutation. Our previous study showed that
treatment with 5-OH-tryptophan and carbidopa in one
PDD-NOS-affected patient with a serotonin re-uptake
transporter mutation (SERT-G56A) and isolated low
5HIAA in the CSF resulted in clinical improvement
and normalization of the brain serotonin turnover [21]. In
this perspective, it would be interesting to investigate
whether all ASD-affected patients with serotonin re-uptake
transporter mutations, such as SERT and PMAT, in com-
bination with low brain serotonin turnover would benefit
from 5-hydroxytryptophan and carbidopa treatment. If
serotonin abnormalities due to hyperserotonemia, iso-
lated low 5HIAA in the CSF, and functional serotonin
re-uptake transporter mutations are essential for the
etiology of ASD, the possibility for new and improved
therapies may be easier to identify. The impact of the
newly identified PMAT mutations leading to loss of
function of the PMAT protein in vitro remains to be
discussed with respect to changes in vivo regarding brain
and peripheral serotonin as well as the impact on dopamine
metabolism. After synaptic release of serotonin, clearance
of serotonin from the synaptic cleft is mediated by the
combined action of membrane transporter proteins suchas SERT, PMAT, and the organic cation transporter 3
(OCT3) [35]. As described in several publications over
the years, SERT is a high-affinity low-capacity transporter
responsible for serotonin re-uptake back into the pre-
synaptic serotoninergic neuron, where it can be recycled
again into pre-synaptic vesicles [35]. In contrast to SERT,
PMAT has been found to be located in the non-
serotoninergic neurons surrounding the serotoninergic
synaps and represents a low-affinity high-capacity trans-
porter [35,36]. Rat brain studies showed that SLC29A4/
PMAT-mRNA was found in various neuron subtypes,
including glutamatergic, GABAergic, and cholinergic
neurons throughout the brain and almost not in mono-
aminergic nuclei. These neurons participate in neuronal
circuitries implicated in locomotion, associative and spatial
memory, and reward-related learning [37].
After uptake of serotonin from the synaptic space by
PMAT-expressing neurons, serotonin will probably be
catabolized to 5HIAA within these neurons. In the adult
human and mouse brain, SLC29A4/PMAT-mRNA and
protein have been demonstrated to be broadly expressed
and abundant in forebrain cortex, olfactory tubercle, hippo-
campus, cerebellum, and epithelial cells of the choroid
plexus [25,36]. The study by Dahlin and coworkers has
shown that PMAT is co-expressed throughout most brain
regions together with the high affinity serotonin transporter
(SERT) and the dopamine transporter (DAT), but is also
found in certain sites that receive monoamine innervations
but lack significant expression of SERT or DAT [36]. In the
event of PMAT mutations with loss of function, such as
PMAT-A138T and PMAT-D326E (Figure 2a–c), we suspect
that serotonin and dopamine clearance become particularly
compromised within those synaptic sites lacking SERT
and DAT expression. The reduced monoamine clearance
from these sites explains the down-regulated catabolism
of monoamines, while the presence of higher monoamine
concentrations within the synaptic space may exert a
negative feedback inhibition through auto-receptors of
local serotonin synthesis within pre-synaptic nerve ter-
minals. However, more studies on the human brain are
required to provide further insight into basic pathways of
monoamine homeostasis in several brain regions among
healthy controls and the alterations among patients with
ASD suffering from SERT and/or PMAT mutations.
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ASD, consistent findings were focal patches of abnormal
laminar cyto-architecture and cortical disorganization
of neurons in layers 4 and 5 of the prefrontal and tem-
poral cortex, whereas variable findings were heterotopias,
loss of cerebellar Purkinje cells, and a reduced number
of synapses [38,39]. In addition to its known neuro-
modulatory role as a neurotransmitter, serotonin acts as
an essential signaling molecule during brain development
enabling normal migration, cerebral cortex differentiation,
and formation of neuronal networks [40,41].
Whole blood serotonin and platelet serotonin content
are increased in about 25 to 30% of the ASD population
and their first-degree relatives. Because the fetal blood–
brain barrier during pregnancy is not yet fully formed,
the fetal brain will be exposed to high serotonin levels,
leading through a negative-feedback mechanism to a
loss of serotonin neurons and a limited outgrowth of
their terminals. This hypothesis has been confirmed by rat
studies using the serotonin agonist 5-methoxytryptamine
between gestational days 12 until postnatal day 20 [42].
Incomplete ASD-behavior has also been observed in
more specific genetic rodent models disrupting early
serotonin neuron development, driven by the pet-1 ETS
gene or Celf6-gene, which resulted in reduced serotonin
levels [43,44]. Likewise, ASD-like behavior has been
observed in both SLC6A4 gene (SERT) knockout mice
and the SLC6A4 Ala56 high activity SERT variant; both
latter models finally result in decreased serotoninergic
signal transmission. A more complete phenotype of ASD
could be observed in Tph2-/- mice via a null mutation of
the gene for TPH2, the rate-limiting enzyme for serotonin
production. In addition to these genetic models, injection
of the serotoninergic neurotoxin, 5,7-dihydroxytryptamine
into the bilateral medial forebrain bundle of mice at birth
also reproduced similar results [41].
These rodent studies underline that during the pre- and
post-natal period a tight regulation of serotonin signaling
between strict boundaries is required to prevent ASD,
because either prenatal exposure to high serotonin through
the placenta or hypo-serotonin conditions perturb early
development of brainstem serotonin neurons and out-
growth of their terminals, where serotonin fails to act
as a signaling molecule for normal brain development.
PET-scan studies in young children with ASD have con-
firmed loss of serotonin production in cerebral cortex and
subcortical structures [14,18,19].
PMAT is widely expressed in all brain areas and skeletal
muscles. In contrast to the high-affinity low-capacity
serotonin membrane transporter SERT, PMAT is a low-
affinity high-capacity transporter for biogenic monoamines
and organic cations. Both SERT and PMAT transporters
cooperate in recycling and degradation of serotonin from
synapses to terminate serotonin signaling. In addition toits wide expression in the brain, PMAT is also expressed
at the apical side of choroid plexus epithelial cells (CSF-
face), where it functions as a major transporter of biogenic
monoamines and xenobiotic cations from cerebrospinal
fluid into the choroid epithelial cells. In Slc29a4-/- mice,
loss of PMAT expression at the apical surface of choroid
plexus was found to impair monoamine and organic
cation uptake from the CSF compartment [45]. Like in
Slc6a4-/- knockout mice, we speculate that loss of PMAT
function due to mutations or deletions of the encoding
gene will diminish serotonin reuptake from synapses and
choroid plexus-mediated clearance of serotonin from
the CSF. During the prenatal period, this may result in a
hyper-serotonin condition with negative feedback inhib-
ition on development of brainstem serotonin neurons and
outgrowth of their axonal branches. At later stages, the
loss of PMAT function further exerts a negative feedback
inhibition through pre-synaptic auto-receptors on local
TPH2-mediated serotonin synthesis, which ultimately leads
to long-term serotonin depletion in subcortical and cortical
areas, as outlined above.
However, the real situation appears more complex for
the following reasons: i) although PMAT mutations are
linked to the ASD population, these mutations in ASD
subjects were inherited from unaffected parents and ii)
despite demonstration of reduced serotonin and dopa-
mine re-uptake by cell cultures expressing two PMAT
mutants in vitro, CSF analysis did show low serotonin
metabolites in some of these patients but not in all cases.
The genome sequencing data indicated that two autistic
subjects with PMAT mutations and functional loss in vitro
associated with low 5HIAA in CSF, had the highest burden
of abnormal serotonin homeostasis genes, as compared
to their siblings and parents, whereas the other autism-
associated candidate genes did not show a higher accu-
mulation for the ASD patients in comparison to their
siblings and parents. In the identical twins with the
PMAT mutation whose CSF 5HIAA levels were normal,
genome sequencing of serotonin homeostasis genes has
not been performed but might improve our understanding
for the normal CSF levels. The fact that PMAT mutations
with functional loss of monoamine re-uptake in vitro is
not invariably associated with reduced serotonin metabol-
ite levels in spinal fluid would suggest that these PMAT
mutations exert a more important pathophysiological
role in the prenatal period of brain development, as
outlined above.
Conclusions
In summary, with our findings we were able to link novel
mutations in SLC29A4 to ASD. In addition to analysis of
serotonin re-uptake transporter genes, exome sequencing
data in ASD and their first-degree relatives should
focus on serotonin homeostasis genes to provide a
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serotonin signaling in ASD. This strategy might offer
the development of new tools to provide a better
pharmacological approach and new therapeutic targets.
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